BPC-157 Use Rose 33-Fold Since 2020

The use of the unapproved peptide BPC-157 surged significantly between 2020 and 2026.

Updated on Sept. 19, 2026 in Healthcare

Isometric editorial illustration of medical vials and a syringe, representing the rise of pharmaceutical peptide use. — The use of the experimental peptide BPC-157 surged 33-fold between 2020 and 2026, driven by online interest despite a lack of FDA approval. AI Illustration. Upload story photo >

Live Poll

Would you trust an experimental supplement that has not been approved by the FDA?

Medical usage of the experimental peptide BPC-157 increased 33-fold between 2020 and 2026. HHS Secretary Robert F. Kennedy Jr. has since encouraged FDA advisors to allow pharmacy compounding of the supplement.

Why it matters

The FDA has not approved BPC-157, yet social media promotion regarding muscle growth and recovery has driven a massive increase in demand for the compound. The potential legitimization of such peptides could create a multibillion-dollar market.

Current data shows 1,039 patients utilized BPC-157 under medical supervision, with 644 reporting symptom improvements despite some experiencing adverse neuropsychiatric and gastrointestinal effects. The broader compounding industry is currently valued at $6.8 billion.

The players

Robert F. Kennedy Jr.

He serves as the HHS Secretary and has advocated for the inclusion of pharmacy-compounded supplements.

Food and Drug Administration

This federal agency is responsible for protecting public health by regulating food, drugs, and other products in the United States.

The details

While patients often use BPC-157 in combination with TB-500 under medical supervision, the FDA has not approved the peptide for human use. Recent demographic data indicates that 96% of users are white and 70% were new consumers of the compound during the study period.

The number of BPC-157 users increased 33-fold between 2020 and 2026.
In July 2026, Robert F. Kennedy Jr. addressed an FDA advisory panel regarding the supplement.

Market Landscape

The potential shift toward legalizing BPC-157 threatens to disrupt the existing FDA compounding regulatory framework, signaling a major move in the peptide industry. This evolution positions compounding pharmacies against traditional pharmaceutical developers in a market expected to reach $3 billion.

Consumers considering the use of BPC-157 should be aware that the compound is currently unapproved by the FDA and linked to potential neuropsychiatric and gastrointestinal side effects. Those currently under medical supervision may see changes in availability if federal compounding rules are updated.

The takeaway

The rapid rise of experimental supplements highlights a growing gap between social media-driven health trends and established clinical approval processes. Patients are encouraged to prioritize FDA-vetted treatments to ensure safety and regulatory oversight.